Cannabinoid–Opioid Interaction in Chronic Pain
Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty–one individuals with chronic pain, on a regimen of twi...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2011-12, Vol.90 (6), p.844-851 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 851 |
|---|---|
| container_issue | 6 |
| container_start_page | 844 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 90 |
| creator | Abrams, D I Couey, P Shade, S B Kelly, M E Benowitz, N L |
| description | Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty–one individuals with chronic pain, on a regimen of twice–daily doses of sustained–release morphine or oxycodone were enrolled in the study and admitted for a 5–day inpatient stay. Participants were asked to inhale vaporized cannabis in the evening of day 1, three times a day on days 2–4, and in the morning of day 5. Blood sampling was performed at 12–h intervals on days 1 and 5. The extent of chronic pain was also assessed daily. Pharmacokinetic investigations revealed no significant change in the area under the plasma concentration–time curves for either morphine or oxycodone after exposure to cannabis. Pain was significantly decreased (average 27%, 95% confidence interval (CI) 9, 46) after the addition of vaporized cannabis. We therefore concluded that vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels. The combination may allow for opioid treatment at lower doses with fewer side effects.
Clinical Pharmacology & Therapeutics (2011); 90 6, 844–851. doi:10.1038/clpt.2011.188 |
| doi_str_mv | 10.1038/clpt.2011.188 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905674571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>905674571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3978-56745a5d7e922315ca55f92403fb4f155e4a2a05b6affd56950136b2a20a76993</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqUwsqIuiCnFH7kkHlHER6VKdCizdXFsYZQ6IU6FuvEf-If8EhJaYGO6O-nR-54eQs4ZnTEqsmtdNd2MU8ZmLMsOyJiB4FECAg7JmFIqI8lFMiInIbz0Zyyz7JiMOKdxxjmMCc3Reyycr135-f7x2Lh-mc59Z1rUnav91Plp_tzW3unpEp0_JUcWq2DO9nNCnu5uV_lDtHi8n-c3i0gLmWYRJGkMCGVqJOeCgUYAK3lMhS1iywBMjBwpFAlaW0IigTKRFBw5xTSRUkzI1S63aevXjQmdWrugTVWhN_UmKEm_K1LWk9GO1G0dQmusalq3xnarGFWDIzU4UoMj1Tvq-Yt98qZYm_KX_pHSA5d7AIPGyrbotQt_HHDBgfGekzvuzVVm-3-ryperfLFcDffwxBfpXn-D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>905674571</pqid></control><display><type>article</type><title>Cannabinoid–Opioid Interaction in Chronic Pain</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Abrams, D I ; Couey, P ; Shade, S B ; Kelly, M E ; Benowitz, N L</creator><creatorcontrib>Abrams, D I ; Couey, P ; Shade, S B ; Kelly, M E ; Benowitz, N L</creatorcontrib><description>Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty–one individuals with chronic pain, on a regimen of twice–daily doses of sustained–release morphine or oxycodone were enrolled in the study and admitted for a 5–day inpatient stay. Participants were asked to inhale vaporized cannabis in the evening of day 1, three times a day on days 2–4, and in the morning of day 5. Blood sampling was performed at 12–h intervals on days 1 and 5. The extent of chronic pain was also assessed daily. Pharmacokinetic investigations revealed no significant change in the area under the plasma concentration–time curves for either morphine or oxycodone after exposure to cannabis. Pain was significantly decreased (average 27%, 95% confidence interval (CI) 9, 46) after the addition of vaporized cannabis. We therefore concluded that vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels. The combination may allow for opioid treatment at lower doses with fewer side effects.
Clinical Pharmacology & Therapeutics (2011); 90 6, 844–851. doi:10.1038/clpt.2011.188</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2011.188</identifier><identifier>PMID: 22048225</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Administration, Inhalation ; Adult ; Analgesics, Opioid - administration & dosage ; Analgesics, Opioid - pharmacokinetics ; Analgesics, Opioid - therapeutic use ; Area Under Curve ; Biological and medical sciences ; Chronic Pain - drug therapy ; Delayed-Action Preparations ; Dronabinol - adverse effects ; Dronabinol - pharmacology ; Drug Administration Schedule ; Drug Synergism ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Morphine - administration & dosage ; Morphine - pharmacokinetics ; Morphine - therapeutic use ; Oxycodone - administration & dosage ; Oxycodone - pharmacokinetics ; Oxycodone - therapeutic use ; Pharmacology. Drug treatments ; Treatment Outcome</subject><ispartof>Clinical pharmacology and therapeutics, 2011-12, Vol.90 (6), p.844-851</ispartof><rights>2011 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3978-56745a5d7e922315ca55f92403fb4f155e4a2a05b6affd56950136b2a20a76993</citedby><cites>FETCH-LOGICAL-c3978-56745a5d7e922315ca55f92403fb4f155e4a2a05b6affd56950136b2a20a76993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fclpt.2011.188$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fclpt.2011.188$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25232512$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22048225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abrams, D I</creatorcontrib><creatorcontrib>Couey, P</creatorcontrib><creatorcontrib>Shade, S B</creatorcontrib><creatorcontrib>Kelly, M E</creatorcontrib><creatorcontrib>Benowitz, N L</creatorcontrib><title>Cannabinoid–Opioid Interaction in Chronic Pain</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty–one individuals with chronic pain, on a regimen of twice–daily doses of sustained–release morphine or oxycodone were enrolled in the study and admitted for a 5–day inpatient stay. Participants were asked to inhale vaporized cannabis in the evening of day 1, three times a day on days 2–4, and in the morning of day 5. Blood sampling was performed at 12–h intervals on days 1 and 5. The extent of chronic pain was also assessed daily. Pharmacokinetic investigations revealed no significant change in the area under the plasma concentration–time curves for either morphine or oxycodone after exposure to cannabis. Pain was significantly decreased (average 27%, 95% confidence interval (CI) 9, 46) after the addition of vaporized cannabis. We therefore concluded that vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels. The combination may allow for opioid treatment at lower doses with fewer side effects.
Clinical Pharmacology & Therapeutics (2011); 90 6, 844–851. doi:10.1038/clpt.2011.188</description><subject>Administration, Inhalation</subject><subject>Adult</subject><subject>Analgesics, Opioid - administration & dosage</subject><subject>Analgesics, Opioid - pharmacokinetics</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Chronic Pain - drug therapy</subject><subject>Delayed-Action Preparations</subject><subject>Dronabinol - adverse effects</subject><subject>Dronabinol - pharmacology</subject><subject>Drug Administration Schedule</subject><subject>Drug Synergism</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morphine - administration & dosage</subject><subject>Morphine - pharmacokinetics</subject><subject>Morphine - therapeutic use</subject><subject>Oxycodone - administration & dosage</subject><subject>Oxycodone - pharmacokinetics</subject><subject>Oxycodone - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Treatment Outcome</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqUwsqIuiCnFH7kkHlHER6VKdCizdXFsYZQ6IU6FuvEf-If8EhJaYGO6O-nR-54eQs4ZnTEqsmtdNd2MU8ZmLMsOyJiB4FECAg7JmFIqI8lFMiInIbz0Zyyz7JiMOKdxxjmMCc3Reyycr135-f7x2Lh-mc59Z1rUnav91Plp_tzW3unpEp0_JUcWq2DO9nNCnu5uV_lDtHi8n-c3i0gLmWYRJGkMCGVqJOeCgUYAK3lMhS1iywBMjBwpFAlaW0IigTKRFBw5xTSRUkzI1S63aevXjQmdWrugTVWhN_UmKEm_K1LWk9GO1G0dQmusalq3xnarGFWDIzU4UoMj1Tvq-Yt98qZYm_KX_pHSA5d7AIPGyrbotQt_HHDBgfGekzvuzVVm-3-ryperfLFcDffwxBfpXn-D</recordid><startdate>201112</startdate><enddate>201112</enddate><creator>Abrams, D I</creator><creator>Couey, P</creator><creator>Shade, S B</creator><creator>Kelly, M E</creator><creator>Benowitz, N L</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201112</creationdate><title>Cannabinoid–Opioid Interaction in Chronic Pain</title><author>Abrams, D I ; Couey, P ; Shade, S B ; Kelly, M E ; Benowitz, N L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3978-56745a5d7e922315ca55f92403fb4f155e4a2a05b6affd56950136b2a20a76993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Administration, Inhalation</topic><topic>Adult</topic><topic>Analgesics, Opioid - administration & dosage</topic><topic>Analgesics, Opioid - pharmacokinetics</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Chronic Pain - drug therapy</topic><topic>Delayed-Action Preparations</topic><topic>Dronabinol - adverse effects</topic><topic>Dronabinol - pharmacology</topic><topic>Drug Administration Schedule</topic><topic>Drug Synergism</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morphine - administration & dosage</topic><topic>Morphine - pharmacokinetics</topic><topic>Morphine - therapeutic use</topic><topic>Oxycodone - administration & dosage</topic><topic>Oxycodone - pharmacokinetics</topic><topic>Oxycodone - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abrams, D I</creatorcontrib><creatorcontrib>Couey, P</creatorcontrib><creatorcontrib>Shade, S B</creatorcontrib><creatorcontrib>Kelly, M E</creatorcontrib><creatorcontrib>Benowitz, N L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abrams, D I</au><au>Couey, P</au><au>Shade, S B</au><au>Kelly, M E</au><au>Benowitz, N L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cannabinoid–Opioid Interaction in Chronic Pain</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2011-12</date><risdate>2011</risdate><volume>90</volume><issue>6</issue><spage>844</spage><epage>851</epage><pages>844-851</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty–one individuals with chronic pain, on a regimen of twice–daily doses of sustained–release morphine or oxycodone were enrolled in the study and admitted for a 5–day inpatient stay. Participants were asked to inhale vaporized cannabis in the evening of day 1, three times a day on days 2–4, and in the morning of day 5. Blood sampling was performed at 12–h intervals on days 1 and 5. The extent of chronic pain was also assessed daily. Pharmacokinetic investigations revealed no significant change in the area under the plasma concentration–time curves for either morphine or oxycodone after exposure to cannabis. Pain was significantly decreased (average 27%, 95% confidence interval (CI) 9, 46) after the addition of vaporized cannabis. We therefore concluded that vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels. The combination may allow for opioid treatment at lower doses with fewer side effects.
Clinical Pharmacology & Therapeutics (2011); 90 6, 844–851. doi:10.1038/clpt.2011.188</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>22048225</pmid><doi>10.1038/clpt.2011.188</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2011-12, Vol.90 (6), p.844-851 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905674571 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Inhalation Adult Analgesics, Opioid - administration & dosage Analgesics, Opioid - pharmacokinetics Analgesics, Opioid - therapeutic use Area Under Curve Biological and medical sciences Chronic Pain - drug therapy Delayed-Action Preparations Dronabinol - adverse effects Dronabinol - pharmacology Drug Administration Schedule Drug Synergism Female Humans Male Medical sciences Middle Aged Morphine - administration & dosage Morphine - pharmacokinetics Morphine - therapeutic use Oxycodone - administration & dosage Oxycodone - pharmacokinetics Oxycodone - therapeutic use Pharmacology. Drug treatments Treatment Outcome |
| title | Cannabinoid–Opioid Interaction in Chronic Pain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A48%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cannabinoid%E2%80%93Opioid%20Interaction%20in%20Chronic%20Pain&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Abrams,%20D%20I&rft.date=2011-12&rft.volume=90&rft.issue=6&rft.spage=844&rft.epage=851&rft.pages=844-851&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/clpt.2011.188&rft_dat=%3Cproquest_cross%3E905674571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=905674571&rft_id=info:pmid/22048225&rfr_iscdi=true |